NR1H4 and metabolic dysfunction-associated steatotic liver disease: FXR deletion results in hepatic steatosis, insulin resistance and hyperglycaemia, with evidence suggesting decreased expression in NAFLD [12,13], and FXR agonism has already shown early promise as a therapeutic strategy in NAFLD [14].